Table 2 Summary of WGS-MRD qPCR assay performance in ALL, HR-NB and EWS.

From: Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma

Patient ID

WGS-MRD target gene

Chr

Breakpoint

Type

Slope value

R2 value

qPCR quantitative range

qPCR sensitivity

ALL-1

CDKN2A/B1

9

21901886

Del

−3.648

0.9993

10−5

10−5

ALL-2

CDKN2A/B2

9

21469564

Del

−3.584

0.9941

10−4

10−5

ALL-3

CDKN2A/B3

9

21948309

Del

−3.571

0.9995

10−5

10−5

ALL-4

CDKN2A/B4

9

21802667

Del

−3.555

0.9982

10−4

10−4

ALL-5

CDKN2A/B5

9

21975749

Del

−3.881

0.9952

10−4

10−5

ALL-6

CDKN2A/B6

9

21968001

Del

−3.516

0.9971

10−4

10−5

HR-NB1

EZH2

7

148541457

Del

−3.516

0.9971

10−4

10−5

HR-NB2

TERT

5

1296732

Dup

−3.472

0.9959

10−4

10−4

HR-NB3

MYCN

2

16013211

Dup

−3.509

0.9975

10−5

10−5

HR-NB4

CNTN51

11

99492525

Del

−3.807

0.9995

10−4

10−4

HR-NB5

CNTN52

11

99812931

Del

−3.363

0.9988

10−5

10−5

HR-NB6

NDST4

4

116044033

Del

−3.395

0.9974

10−4

10−4

EWS-1

CDKN2A

9

22035192

Del

−3.291

0.9959

10−5

10−5

EWS-2

CCDC117

22

29170280

Del

−3.363

0.9993

10−4

10−5

EWS-3

PPP2R5

14

10234781

Dup

−3.341

0.9867

10−5

10−5

EWS-4

CPEB4

5

173327179

Inv

−3.54

0.9927

10−4

10−4

EWS-5

SnoU13

1

231036549

Del

−3.311

0.9993

10−4

10−4

EWS-6

RASGRF2

5

80404590

Del

−3.875

0.999

10−4

10−4

  1. ALL acute lymphoblastic leukaemia, HR-NB high-risk neuroblastoma, EWS Ewing sarcoma, Chr chromosome, Amp amplification, Del deletion, Dup duplication, Inv inversion.
  2. CDKN2A/B1–6, CNTN51,2: see Supplementary Table 1.